keyword
https://read.qxmd.com/read/38505463/non-celiac-enteropathy-and-olmesartan-an-essential-consideration
#1
Sotirios G Doukas, Panagiotis G Doukas, Sugirdhana Velpari
Emerging evidence has shed light on non-celiac causes of enteropathy in recent years, presenting a diagnostic challenge for clinicians. This study discusses the diagnostic challenges related to non-celiac enteropathy, specifically focusing on olmesartan-induced enteropathy (OIE). A 73-year-old lady presented to the emergency department with a six-month history of watery diarrhea exacerbated by food intake and significant weight loss. The patient at admission was found to be dehydrated with severe hypokalemia and hypocalcemia...
February 2024: Curēus
https://read.qxmd.com/read/38112838/predictors-of-subsequent-celiac-disease-seropositivity-in-patients-diagnosed-with-duodenal-villus-atrophy-on-upper-endoscopy
#2
JOURNAL ARTICLE
Charlotte K Ching, Michael Lyudmer, Suzanne Lewis, Suneeta Krishnareddy, Peter H R Green, Benjamin Lebwohl
BACKGROUND: The diagnosis of celiac disease (CD) is based on positive IgA autoantibodies to tissue transglutaminase (TTG IgA) and confirmatory histopathology demonstrating duodenal villus atrophy (VA). Diagnostic challenges can occur when VA is found on duodenal biopsies in patients without prior CD serologies. AIMS: To characterize the predictors of CD seropositivity in patients with VA on biopsy without prior CD serologies. METHODS: We performed a retrospective cohort study of patients found to have duodenal VA on histopathology from 2010 to 2020 who did not have prior CD serologies measured and who had them checked after their biopsy...
December 19, 2023: Digestive Diseases and Sciences
https://read.qxmd.com/read/37925200/olmesartan-associated-sprue-like-enteropathy
#3
JOURNAL ARTICLE
Laisa Socorro Briongos-Figuero, Jorge Cuevas-González
No abstract text is available yet for this article.
November 4, 2023: Lancet
https://read.qxmd.com/read/37559845/a-rare-case-of-olmesartan-associated-enteropathy-successfully-managed-with-steroid-taper
#4
Angela Xue, Mark R Fowler, Jan Silverman, Emily Sturkie, Evan Raff
Olmesartan is a commonly used antihypertensive medication belonging to the class of angiotensin II receptor blockers. Though generally well-tolerated, olmesartan can rarely cause olmesartan-associated enteropathy (OAE) with non-bloody diarrhea, weight loss, abdominal pain, and vomiting. Patients may develop enteropathy months to years after drug initiation. In severe cases, patients may develop complications that require hospitalization. Diagnosis is often delayed due to unfamiliarity of OAE, nonspecific presenting symptoms, and normal-appearing gross endoscopic findings...
July 2023: Curēus
https://read.qxmd.com/read/37559251/angiotensin-receptor-blocker-related-sprue-like-enteropathy-review-of-food-and-drug-administration-adverse-event-reporting-system
#5
JOURNAL ARTICLE
Ryan Meader, Sam Papasotiriou, Hardeep Ahdi, Hoang Dang, Eli D Ehrenpreis
BACKGROUND: Sprue-like enteropathy (SE) related to olmesartan use was first reported in 2012. In 2017, the manufacturer of Benicar paid $300 million for 2300 claims for olmesartan-related SE. OBJECTIVE: A study in 2019 suggested that SE was related to olmesartan and with the possibility of angiotensin receptor blocker (ARB) class effect. To further characterize this condition, our group examined reports of ARB-related SE to Food and Drug Administration Adverse Event Reporting System (FAERS)...
August 9, 2023: Annals of Pharmacotherapy
https://read.qxmd.com/read/37035266/candesartan-induced-enteropathy-that-mimics-celiac-disease-in-a-90-year-old-patient
#6
Lydia M L Holtgrewe, Harald Dippel, Helgard Weckauf, Stephan Linnemüller, Frank Schuppert
Sprue-like enteropathy (SLE) is a clinical syndrome similar to celiac disease and has been associated with the use of various angiotensin receptor blockers (ARBs), a class of medications frequently used in the management of hypertension. Currently, there has only been one documented case report which has observed this occurrence with the use of the ARB candesartan. A 90-year-old female patient presented with chronic diarrhea and weight loss of unclear etiology. Diagnostic esophagogastroduodenoscopy and ileocolonoscopy were macroscopically unremarkable, but histological samples revealed complete villous atrophy, chronic mucosal inflammation, and intraepithelial T-lymphocytic infiltration...
2023: Case Reports in Gastroenterology
https://read.qxmd.com/read/36904178/fecal-calprotectin-elevations-associated-with-food-intolerance-malabsorption-are-significantly-reduced-with-targeted-diets
#7
JOURNAL ARTICLE
Wolfgang J Schnedl, Simon Michaelis, Dietmar Enko, Harald Mangge
Inflammatory bowel disease (IBD) involves two clinically defined entities, namely Crohn's disease and ulcerative colitis. Fecal calprotectin (FCAL) is used as a marker to distinguish between organic IBD and functional bowel disease in disorders of the irritable bowel syndrome (IBS) spectrum. Food components may affect digestion and cause functional abdominal disorders of the IBS spectrum. In this retrospective study, we report on FCAL testing to search for IBD in 228 patients with disorders of the IBS spectrum caused by food intolerances/malabsorption...
February 27, 2023: Nutrients
https://read.qxmd.com/read/36564092/olmesartan-associated-sprue-like-enteropathy
#8
JOURNAL ARTICLE
Naoki Aoyama, Tetsuro Inokuma, Yuki Nakanishi, Akihisa Fukuda
No abstract text is available yet for this article.
December 23, 2022: BMJ Case Reports
https://read.qxmd.com/read/35945664/the-histologic-spectrum-of-arb-induced-gastritis
#9
JOURNAL ARTICLE
Tanner Storozuk, Ian Brown, Stephen Lagana, Maria Westerhoff, Namrata Setia, John Hart, Lindsay Alpert
AIMS: Olmesartan, an angiotensin receptor blocker (ARB) used for hypertension management, is known to cause a sprue-like enteropathy in a subset of patients. Rare cases of gastritis occurring with ARB use have also been reported, but the histologic features of ARB-induced gastritis and the response to drug cessation have not been examined in a dedicated case series. METHODS AND RESULTS: Cases of suspected ARB-induced gastritis were identified from the pathology archives of 4 institutions...
August 9, 2022: Histopathology
https://read.qxmd.com/read/35898826/a-case-report-of-olmesartan-associated-sprue-like-enteropathy-diagnosis-and-healing-confirmed-by-capsule-endoscopy
#10
Yoshiharu Yamaguchi, Takahiro Miwa, Ryo Murakami, Akane Sugimura, Kazuhiro Yamamoto, Tomoya Sugiyama, Yasuhiro Tamura, Shinya Izawa, Masahide Ebi, Yasushi Funaki, Naotaka Ogasawara, Makoto Sasaki, Kunio Kasugai
Herein, we describe a case of olmesartan-related sprue-like enteropathy in which improvement in villous atrophy was confirmed by small-bowel capsule endoscopy (CE). We successfully treated a 66-year-old man with a chief complaint of loose diarrhea. The patient had persistent watery diarrhea 10 times a day and experienced a weight loss of 9 kg in 3 months. An abdominal computed tomography scan showed fluid retention in the small intestine. Blood test results revealed no inflammatory reaction. Esophagogastroduodenoscopy detected villous atrophy in the stomach and duodenum...
April 2023: DEN Open
https://read.qxmd.com/read/35711393/angiotensin-receptor-blockers-associated-enteropathy-brief-report
#11
JOURNAL ARTICLE
Neha Gosai, Falgun Gosai
The current literature has shown equivocal results regarding the association of Olmesartan and other angiotensin receptor blockers (ARBs) use and the presence of Celiac sprue-like enteropathy (CSLE). Various factors affecting the association are- patient population under study, geographic area, and duration of use of medication. Various case reports/case series and observational studies have shown the mixed results regarding an association. We have tried to answer a question what exists in the literature regarding the angiotensin receptor blockers related sprue like enteropathy...
2022: Journal of Community Hospital Internal Medicine Perspectives
https://read.qxmd.com/read/35058164/-olmesartan-and-enteropathy-a-decade-later-a-perhaps-not-so-exceptional-association
#12
C Albaladejo Blanco, L Martínez Capilla, J A Martín García
Olmesartan is a potent angiotensin II receptor antagonist commonly used in the treatment of high blood pressure. During the last decade, several cases of sprue-like enteropathy have been described associated with the use of this drug - with severe clinical involvement that requires hospitalization - but fortunately with complete remission after its discontinuation. We present the case of a multi-pathological 82-year-old woman with a chronic diarrhoeal syndrome that resulted in a weight loss of 20kg over the last three months...
January 17, 2022: Hipertensión y Riesgo Vascular
https://read.qxmd.com/read/34540405/olmesartan-induced-enteropathy-a-report-of-an-unusual-cause-of-chronic-diarrhea
#13
Christos Sotiropoulos, Eftichia Sakka, Georgia Diamantopoulou, Georgios J Theocharis, Konstantinos C Thomopoulos
Olmesartan, an angiotensin II receptor blocker indicated in the treatment of hypertension, has been associ-ated with a seronegative sprue-like enteropathy that should be considered in the differential diagnosis of patients with unexplained chronic diarrhoea. It typically presents with severe chronic diarrhoea, considerable weight loss, and villous atrophy on biopsy and may be difficult to recognize because of its clinical and histological similarities to other clinical entities. Practically, discontinuation of the drug leads to dramatic recovery of the symptoms...
August 2021: Curēus
https://read.qxmd.com/read/34480728/olmesartan-associated-sprue-like-enteropathy-diagnosed-by-capsule-endoscopy-and-double-balloon-endoscopy
#14
JOURNAL ARTICLE
Daisuke Taguchi, Takashi Ibuka, Masamichi Arao, Taku Mizutani, Noritaka Ozawa, Masaya Kubota, Yohei Shirakami, Makoto Shiraki, Hiroshi Araki, Masahito Shimizu
Sprue-like enteropathy associated with olmesartan is characterized by villous atrophy in the duodenum. We report the case of an 81-year-old woman diagnosed with olmesartan-associated sprue-like enteropathy with no villous atrophy in the duodenum. The patient had been taking olmesartan for 10 years and complained of diarrhea and weight loss. Despite undergoing general treatment for 2 months, her symptoms showed no improvement. Gastrointestinal endoscopy and pathological findings showed no villous atrophy in the duodenum...
December 2021: Clinical Journal of Gastroenterology
https://read.qxmd.com/read/34430010/cutaneous-ulcers-in-association-with-sprue-like-enteropathy-secondary-to-losartan
#15
Francis Essien, Juakiem Wassem, Joshua Tate, Jared Roberts
Losartan is an angiotensin II receptor blocker (ARB) which may cause severe sprue-like enteropathy (SLE) with skin manifestation. Clinicians should be informed of this side effect and its reversibility after cessation of the drug.
August 2021: Clinical Case Reports
https://read.qxmd.com/read/34378440/sprue-like-enteropathy-and-liver-injury-a-rare-emerging-association-with-olmesartan
#16
JOURNAL ARTICLE
Mihir Odak, Ndausung Udongwo, Nasam Alfraji, Min Zheng, Saddam Zaidi
Olmesartan-induced enteropathy is an underreported phenomenon, first described in 2012. While olmesartan's antihypertensive properties were confirmed early on, its association with a sprue-like enteropathy was subsequently noted. Although this association has been reported with olmesartan, there have been few reports of this association with other angiotensin-receptor blockers. We present a case of a 79-year-old male who presented with diarrhea, weight loss, jaundice, and transaminitis. Further history revealed that he had been taking olmesartan 40 mg daily for hypertension...
January 2021: Journal of Investigative Medicine High Impact Case Reports
https://read.qxmd.com/read/34334714/an-unusual-cause-of-diarrhoea-case-report-and-literature-review-of-olmesartan-associated-enteropathy
#17
REVIEW
Paula Antonia Mauloni, Federica Capuani, Clara Paone, Giovanni Marasco, Lara Bellacosa, Rosanna Francesca Cogliandro, Cesare Cremon, Giovanni Barbara, Francesco Vasuri, Vincenzo Stanghellini
Olmesartan is an angiotensin II receptor blocker, approved in 2002 by the Food and Drug Administration for the treatment of hypertension. During chronic therapy with olmesartan, sprue-like enteropathy can occur, being mainly characterised by non-bloody diarrhoea, weight loss and variable degrees of duodenal mucosal damage, which resolved after withdrawal of olmesartan. We hereby report the case of a 77-year-old, poli-treated male patient with a 3-month history of diarrhoea, vomiting and weight loss, associated with severe intestinal villous atrophy and lymphocytic infiltration of gastric and colonic mucosa...
December 1, 2021: European Journal of Gastroenterology & Hepatology
https://read.qxmd.com/read/33195364/evaluation-of-non-dietary-alternatives-for-treatment-of-adults-with-celiac-disease
#18
JOURNAL ARTICLE
Hugh James Freeman
No abstract text is available yet for this article.
2020: Frontiers in Nutrition
https://read.qxmd.com/read/32864026/severe-sprue-like-enteropathy-and-colitis-due-to-olmesartan-lessons-learned-from-a-rare-entity
#19
Daniel R Bashari
Olmesartan is an angiotensin II receptor blocker (ARB) drug approved in 2002 for the treatment of hypertension. Since 2012, there have been reports of a rare adverse effect suspected to be related to its use. The author presents a case of a 63-year-old female with refractory gastrointestinal (GI) symptoms including diarrhea with associated weight loss and severe electrolyte abnormalities necessitating hospitalization. An extensive inpatient evaluation ensued and was initially unremarkable. Esophagogastroduodenoscopy (EGD) discovered an endoscopically normal duodenum that was biopsied and notably revealed villous atrophy and intraepithelial lymphocytosis...
August 2020: Gastroenterology Research
https://read.qxmd.com/read/32789126/olmesartan-induced-enteropathy-a-case-of-recurrent-diarrhoea
#20
JOURNAL ARTICLE
Ana Rita Fernandes Matos, Elisabete Coelho, Sofia Caridade
A 77-year-old man with arterial hypertension and dyslipidaemia, treated with olmesartan/hydrochlorothiazide and simvastatin, was admitted with a 3-week history of anorexia, nausea, vomiting, profuse diarrhoea and weight loss. He was dehydrated and blood tests showed acute kidney injury. The aetiological study was inconclusive. The patient had a favourable clinical evolution during hospitalization and was discharged. However, after about 10 days at home, he was re-admitted to hospital with the same clinical presentation...
2020: European Journal of Case Reports in Internal Medicine
keyword
keyword
82038
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.